Effects of tenidap and nonsteroidal antiinflammatory drugs on the response of cultured human T cells to interleukin 2 in rheumatoid arthritis

Journal of Rheumatology

Volumn 24, Issue 8, 1997, Pages 1467-1470

  Hall, Vicky C ^a,b   Wolf, Robert E ^a,c  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

^b Section of Rheumatology   (United States)

^c Department of Medicine ^*  (United States)

Author keywords

cultured human T cells; interleukin 2; nonsteroidal antiinflammatory drugs; rheumatoid arthritis; tenidap

Indexed keywords

ANTIINFLAMMATORY AGENT; IBUPROFEN; INDOMETACIN; INTERLEUKIN 2; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC; TENIDAP;

ARTICLE; CELL PROLIFERATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; T LYMPHOCYTE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; BINDING SITES; CELL DIVISION; CELLS, CULTURED; CYCLOOXYGENASE INHIBITORS; HUMANS; INDOLES; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; T-LYMPHOCYTES;

EID: 0030760234     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Zvaifler NJ: Pathogenesis of the joint disease of rheumatoid arthritis. Am J Med 1983;(suppl)75:3-83.
2. Firestein GS, Tsai V, Zvaifler NJ: Cellular immunity in the joints of patients with rheumatoid arthritis and other forms of chronic synovitis. Rheum Dis Clin North Am 1987;13:191-213.
3. Sewell KL, Trentham DE: Pathogenesis of rheumatoid arthritis. Lancet 1993;341:283-6.
4. Wilkins JA, Warrington RJ, Sigurdson SL, Rutherford WJ: The demonstration of interleukin-2 like activity in the synovial fluids of rheumatoid arthritis patients. J Rheumatol 1983;10:109-13.
5. Lemm G, Warnatz H: Evidence for enhanced interleukin 2 (IL-2) secretion and IL-2 receptor presentation by synovial fluid lymphocytes in rheumatoid arthritis. Clin Exp Immunol 1986;64:71-9.
6. Barrera P, Boerbooms AMT, Janssen EM, et al: Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis. Arthritis Rheum 1993;36:1070-9.
7. Farahat MN, Yanni G, Poston R, Panayi G: Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993;52:870-5.
8. McKenna RM, Ofosu-Appiah W, Warrington RJ, Wilkins JA: Interleukin 2 production and responsiveness in active and inactive rheumatoid arthritis. J Rheumatol 1986;13:28-32.
9. Wolf RE, Hall VC: Interleukin-2 production and effect of thymosin fraction 5 on interleukin-2 production in rheumatoid arthritis. J Rheumatol 1987;14:898-901.
10. Warrington RJ: Interleukin-2 abnormalities in systemic erythematosus and rheumatoid arthritis. A role for overproduction of interleukin-2 in human autoimmunity? J Rheumatol 1988;15:616-20.
11. Alcocer-Varela J, Laffon A, Alarcon-Segovia D: Differences in the production of and/or the response to interleukin-2 by T lymphocytes from patients with the various connective tissue diseases. Rheumatol Int 1984;4:39-44.
12. Combe B, Pope RM, Fischbach M, Darnell B, Baron S, Talal N: Interleukin-2 in rheumatoid arthritis: Production of and response to interleukin-2 in rheumatoid synovial fluid, synovial tissue and peripheral blood. Clin Exp Immunol 1985;59:520-8.
13. Vane JR: Inhibition of prostaglandin synthesis as a mechanism of action of aspirin-like drugs. Nature (New Biol) 1977;231:232-5.
14. Carty TJ, Showell HJ, Loose LD, Kadin SB: Inhibition of both 5-lipoxyaenase and cyclooxygenase pathways of arachidonic acid metabolism by CP-66,248 (abstr). Arthritis Rheum 1988;(suppl)31:S89.
15. Moilanen E, Alanko J, Azmawi Z, Vapaatalo H: CP-66,248, a new anti-inflammatory agent, is a potent inhibitor of leukotriene B4 and prostanoid synthesis in human polymorphonuclear leukocytes in vitro. Eicosanoids 1988;1:35-9.
16. Wolf RE, Hall VC: Inhibition of in vitro proliferative response of cultured T lymphocytes to interleukin-2 by gold sodium thiomalate. Arthritis Rheum 1988;31:176-81.
17. Lipsky PE, Ziff M: Inhibition of antigen- and mitogen-induced human lymphocyte proliferation by gold compounds. J Clin Invest 1977;59:455-66.
18. Lorber A, Jackson WH, Simon TM: Effects of chrysotherapy on cell mediated immune response. J Rheumatol 1982;(suppl 8)9:37-45.
19. Cannon GW, Cole BC, Ward JR: Differential effects of in vitro gold sodium thiomalate on the stimulation of human peripheral blood mononuclear cells by Mycoplasma arthritidis T cell mitogen, concanavalin A, and phytohemagglutinin. J Rheumatol 1986;13:52-7.
20. Lipsky PE, Ziff M: The effects of D-penicillamine on mitogen-induced human lymphocyte proliferation: Synergistic inhibition by D-penicillamine and copper salts. J Immunol 1978;120:1006-13.
21. Salmeron G, Lipsky PE: Immunosuppressive potential of antimalarials. Am J Med 1983;(suppl)75:19-24.
22. Panush RS: Effects of certain antirheumatic drugs on normal human peripheral blood lymphocytes: Inhibition of mitogen- and antigen stimulated incorporation of tritiated thymidine. Arthritis Rheum 1976;19:907-17.
23. Gordon D, Lewis GP: Effects of piroxicam on mononuclear cells. Comparison with other antirheumatic drugs. Inflammation 1984;(suppl)8:S87-S102.
24. Goodwin JS, Selinger DS, Messner RP: Effects of indomethacin on humoral and cellular immunity in man (abstr). Clin Res 1977;25:358A.
25. Goodwin JS, Ceuppens JL: Effects of nonsteroidal antiinflammatory drugs on immune function. Semin Arthritis Rheum 1983; (suppl 1)13:134-43.
26. Ceuppens JL, Rodriguez MA, Goodwin JS: Nonsteroidal antiinflammatory agents inhibit the synthesis of IgM rheumatoid factor in vitro. Lancet 1982;1:528-31.
27. Blackburn WD, Heck LW, Loose LD, Eskra JD, Carty TJ: Inhibition of 5-lipoxygenase product formation and polymorphonuclear cell degranulation by tenidap sodium in patients with rheumatoid arthritis. Arthritis Rheum 1991;34:204-10.
28. McDonald B, Loose L, Rosenwasser LJ: The influence of a novel arachidonate inhibitor, CP-66,248 on the production and activity of human monocyte IL-1 (abstr). Arthritis Rheum 1988;(suppl)31:S17.
29. Littman BH, Carlson PL, Loose LD, Sanders KM: Effects of gold sodium thiomalate and tenidap sodium (CP-66,248-2) on a model of macrophage differentiation using HL-60 cells. Arthritis Rheum 1990;33:29-36.
30. Panes J, Russell JM, Wolf RE, Wallace JL, Granger DN: Effects of tenidap on leukocyte-endothelial cell adhesion in mesenteric venules. J Rheumatol 1995;22:444-9.
31. Katz P, Borger AP, Loose LD: Evaluation of CP-66,248 (5-chloro-2, 3-dihydro-2-0x0-3-(2-thienylcarbonyl)-indole-1-carbox amine) in rheumatoid arthritis (abstr). Arthritis Rheum 1988;(suppl)31:S52.
32. Littman BH, Drury CE, Zimmerer RO, Stack CB, Law CG: Rheumatoid arthritis treated with tenidap and piroxicam. Arthritis Rheum 1995;38:29-37.
33. Kirby DS, Loose LD, Weiner ES, Wilhelm FE, Shanahan WR, Ting N: Tenidap vs naproxen treatment of rheumatoid arthritis (abstr). Arthritis Rheum 1993;(suppl)36:S112.
34. Loose LD, Weiner ES, Kirby DS, Wilhelm FE, Shanahan WR: Tenidap vs naproxen vs placebo in rheumatoid arthritis: A 2-week study in patients with knee effusions (abstr). Arthritis Rheum 1993;(suppl)36:S112.